Suda Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 5:03 AM
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
|Primary activities||Development and commercialisation of pharmaceutical products through new methods of delivery.|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||55 Howe Street Level 1 Unit 12 Osborne Park WA 6017 Australia|
|Phone / Fax||61 8 6142 5555 / 61 8 9443 8858|
|Share registry||ADVANCED SHARE REGISTRY SERVICES|
Suda Pharmaceuticals does not pay dividends.
As of May 2021, following are the company executives and directors listed on Suda Pharmaceuticals.
|Dr. Michael Baker||CEO, MD, CTO & Director||315.46k|
|Mr. Stephen John Carter||Consultant||286.4k|
|Mr. David Phillips||Exec. Director||193.8k|
|Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA||Company Sec. & CFO||59|
|Dr. Richard Franklin||Project Director & Member of Scientific Advisory Board|
|Tony Macintyre||GM & CTO|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Suda Pharmaceuticals is 12.69M and its enterprise value is 7.3M. The enterprise value to revenue ratio of SUD is 12.95.
Companies similar to Suda Pharmaceuticals (SUD)
Suda Pharmaceuticals (ASX:SUD) Frequently Asked Questions
1. What is Suda Pharmaceuticals's Stock Symbol?
Suda Pharmaceuticals trades on ASX under the ticker symbol "SUD".
2. What is Suda Pharmaceuticals's stock price today?
One share of SUD stock can currently be purchased for approximately $0.033.
3. How can I contact Suda Pharmaceuticals?
Suda Pharmaceuticals's mailing address is 55 Howe Street Level 1 Unit 12 Osborne Park WA 6017 Australia. The company can be reached via phone at 61 8 6142 5555.
4. What is Suda Pharmaceuticals's official website?
The official website of Suda Pharmaceuticals is http://sudapharma.com.
5. Which share registry manages Suda Pharmaceuticals's stock?
Suda Pharmaceuticals's stock is managed by ADVANCED SHARE REGISTRY SERVICES.